{"id":"dermatan-sulfate","rwe":[{"pmid":"41901230","year":"2026","title":"Influence of Propolis-Containing Nonwoven PLGA Dressings on Dermatan and Chondroitin Sulfate Dynamics During Burn-Wound Healing.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41872350","year":"2026","title":"Change in the chondroitin/dermatan structure in distal lung tissue from COPD patients.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41837196","year":"2026","title":"Case Report: Compound heterozygous mutations in the IDUA gene causing mucopolysaccharidosis type I with uterine developmental abnormality.","finding":"","journal":"Frontiers in pediatrics","studyType":"Clinical Study"},{"pmid":"41835542","year":"2026","title":"Inhibition of Dermatan Sulfate Epimerase 1 by Substituted Glucuronic Acids.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"41752037","year":"2026","title":"Integrating Bidirectional Mendelian Randomization with Multi-Omics Reveals Causal Serum Metabolites and Novel Metabolic Drivers of Multiple Myeloma.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"}],"tags":[{"label":"dermatan sulfate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"B01AX04","category":"atc"},{"label":"Active","category":"status"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["dermatan sulfate","dermatan sulfate sodium"],"offLabel":[],"synonyms":["dermatan sulfate","dermatan sulfate sodium"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"dermatan sulfate","explanation":"Imagine dermatan sulfate as a key that fits into a specific lock on a cell. When it binds, it can turn on or off certain cellular activities, which can help to treat various diseases. This process is complex and involves many molecular interactions, but essentially, dermatan sulfate helps to regulate the behavior of cells and tissues.","oneSentence":"Dermatan sulfate is thought to work by interacting with specific cellular receptors or enzymes to modulate biological processes.","technicalDetail":"Dermatan sulfate is a glycosaminoglycan that may interact with various cell surface receptors, such as proteoglycans or integrins, to modulate signaling pathways and influence cellular behavior."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2973","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=dermatan%20sulfate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dermatan sulfate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:33:53.254754","biosimilars":[],"competitors":[{"drugName":"defibrotide","drugSlug":"defibrotide","fdaApproval":"2016-03-30","patentExpiry":"Jun 22, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fondaparinux","drugSlug":"fondaparinux","fdaApproval":"2001-12-07","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"caplacizumab","drugSlug":"caplacizumab","fdaApproval":"2019-02-06","relationship":"same-class"}],"genericName":"dermatan sulfate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"defibrotide","brandName":"defibrotide","genericName":"defibrotide","approvalYear":"2016","relationship":"same-class"},{"drugId":"fondaparinux","brandName":"fondaparinux","genericName":"fondaparinux","approvalYear":"2001","relationship":"same-class"},{"drugId":"caplacizumab","brandName":"caplacizumab","genericName":"caplacizumab","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03428711","phase":"PHASE2","title":"Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis","status":"COMPLETED","sponsor":"Quovadis Associazione","startDate":"2018-03-26","conditions":["Superficial Venous Thrombosis of Leg, Secondary Prevention"],"enrollment":560,"completionDate":"2024-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UMLSCUI":"C0011602","ChEMBL_ID":"CHEMBL3707304","DRUGBANK_ID":"DB15880","PUBCHEM_CID":"32756","SNOMEDCT_US":"102693004","MESH_DESCRIPTOR_UI":"D003871"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3442,"therapeuticAreas":["Dermatology"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AX04","allCodes":["B01AX04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 27","pmid":"41901230","title":"Influence of Propolis-Containing Nonwoven PLGA Dressings on Dermatan and Chondroitin Sulfate Dynamics During Burn-Wound Healing.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 23","pmid":"41872350","title":"Change in the chondroitin/dermatan structure in distal lung tissue from COPD patients.","journal":"Scientific reports"},{"date":"2026","pmid":"41837196","title":"Case Report: Compound heterozygous mutations in the IDUA gene causing mucopolysaccharidosis type I with uterine developmental abnormality.","journal":"Frontiers in pediatrics"},{"date":"2026 Mar 10","pmid":"41835542","title":"Inhibition of Dermatan Sulfate Epimerase 1 by Substituted Glucuronic Acids.","journal":"ACS omega"},{"date":"2026 Feb 16","pmid":"41752037","title":"Integrating Bidirectional Mendelian Randomization with Multi-Omics Reveals Causal Serum Metabolites and Novel Metabolic Drivers of Multiple Myeloma.","journal":"International journal of molecular sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"dermatan sulfate","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Dermatan sulfate is a small molecule drug in the dermatan sulfate class, but information on its development, ownership, and commercial status is not available. Its mechanism of action and target are also unknown. Dermatan sulfate is not FDA-approved for any indications, and its pharmacokinetic properties, such as half-life and bioavailability, are not documented. As a result, there is limited information available on this compound. Further research is needed to understand its potential therapeutic applications and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}